Multiple myeloma is treated with combinations of drugs from multiple classes, and regimens shift substantially every few years as new agents gain approval. Three-drug versus four-drug induction regimens, maintenance duration, and choice among anti-CD38 antibodies and BCMA-targeted therapies are all active areas of clinical debate where close-substitute options exist.
Data from CMS Open Payments (2023–2024) · last checked
These are the close-substitute branded therapies your oncologist may choose among for multiple myeloma. Generic and biosimilar options may also be available depending on line of therapy.
Across all oncologists in our index (all cancer types), these are the companies making these multiple myeloma drugs, summed across their latest reported year of disclosures. Payments include both general and research categories; see methodology for the split.
| Manufacturer | Total disclosed to oncologists (latest year) |
|---|---|
| Pfizer | $8,033,132 |
| Takeda | $2,358,190 |
| Amgen | $1,955,252 |
| Sanofi | $852,121 |
| Legend Biotech | $120,080 |
| Johnson & Johnson | $1,618 |
Active multiple myeloma trials in our database where one or more research-payment records (tied to the trial's NCT ID) are disclosed in CMS Open Payments. We show the disclosed principal investigators and amounts. The presence of research payments on a trial is expected — industry-funded clinical trials pay the physicians running them for site work — but knowing the scale gives you useful context.
Sponsor: Regeneron Pharmaceuticals · sponsor also appears in the payment records
$3,394,180
5
Sponsor: BeOne Medicines
$2,369,355
5
Sponsor: AbbVie · sponsor also appears in the payment records
$1,777,706
5
Sponsor: Regeneron Pharmaceuticals · sponsor also appears in the payment records
$1,524,060
5
Sponsor: Regeneron Pharmaceuticals · sponsor also appears in the payment records
$1,200,308
5
Sponsor: Regeneron Pharmaceuticals · sponsor also appears in the payment records
$601,089
5
Sponsor: AbbVie · sponsor also appears in the payment records
$457,620
5
Sponsor: Regeneron Pharmaceuticals · sponsor also appears in the payment records
$104,008
2
Sponsor: National Cancer Institute (NCI)
$84,048
1
Sponsor: Irene Ghobrial, MD
$78,884
1
+ 9 additional trials with cross-reference data. Browse all multiple myeloma trials →
A financial relationship between a physician and a manufacturer is not, on its own, a problem — it is the expected context of modern drug development. The purpose of federal disclosure is to let you ask informed questions, not to make the decision for you.
Medical disclaimer: This page aggregates public federal data and is not medical advice. Drug choice for any individual patient depends on stage, biomarker profile, prior therapy, comorbidities, and patient preference — decisions that must be made with your licensed care team.
About the payment data: Figures are disclosed by manufacturers to CMS under the Physician Payments Sunshine Act (42 U.S.C. §1320a-7h). Presence of payments is not a conflict of interest. Physicians who believe a record is wrong file a correction through the CMS dispute process.
Sources: CMS Open Payments · ClinicalTrials.gov · Data fetched: 2026-04-21 · full methodology